Pheon Therapeutics
Generated by Meeveem AI
"Engineering targeted antibody-drug conjugates to treat hard-to-treat solid tumors"
London
•11 - 50 Employees
•Biotechnology
About Pheon Therapeutics
Pheon Therapeutics develops next generation antibody-drug conjugates (ADCs) that deliver potent cytotoxic agents directly to cancer cells. The company combines monoclonal antibodies against novel and validated targets with either proprietary payloads or off-the-shelf linker combinations. This target-specific approach balances safety and efficacy for each programme, rejecting one-size-fits-all engineering. Built on two decades of ADC expertise and backed by specialist investors, Pheon is advancing its lead asset into clinical development whilst building a proprietary pipeline for hard-to-treat solid tumors. The company is guided by a leadership team with deep experience in ADC engineering, clinical strategy, and oncology development.
20
Team Members
2022
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A future where patients with hard-to-treat solid tumors have access to precisely targeted therapies that deliver meaningful clinical outcomes without compromising quality of life.
Our Mission
Pheon exists to develop differentiated antibody-drug conjugates that address unmet medical needs in hard-to-treat solid tumors by combining novel targets with optimised payloads tailored to each therapeutic target.